Galmed Pharmaceuticals Ltd.
GLMD
$0.52
$0.0511.19%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -37.14% | -37.57% | -48.26% | -15.56% | -8.75% |
| Total Depreciation and Amortization | -- | -100.00% | -100.00% | 131.25% | 167.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 35.06% | 404.29% | 279.24% | 265.84% | 272.88% |
| Change in Net Operating Assets | 225.27% | -119.37% | 167.42% | 72.55% | -651.52% |
| Cash from Operations | -7.40% | -28.91% | 7.67% | 16.82% | 4.19% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -203.78% | -300.50% | -1,461.80% | -1,390.76% | -238.88% |
| Cash from Investing | -203.78% | -300.50% | -1,461.80% | -1,390.76% | -238.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.73% | -0.62% | 164.11% | 66.53% | 42.05% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.73% | -0.62% | 164.11% | 66.53% | 42.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -136.99% | -174.02% | 276.90% | 1,706.31% | 111.67% |